Gene therapy clinical trials to surge in 2023, speculating optimism

Gene therapy was first used in the field of therapeutics and there have been many up and down. Yet, the development of gene therapy has reached an important turning point, as shown by the rise in the availability of gene therapy products. Gene therapy has an optimistic future, based on the drugs that are now approved or that are awaiting approval, as well as the numerous clinical trials that have been conducted in this area.

For drug firms, decision-makers, and academics, the trend of changes in gene therapy techniques, vectors, and targets may be instructive.

Although cancer studies are for a variety of diseases, the majority of them are for the treatment of solid tumours. This is most likely because viral vectors can deliver and remain in solid tumours more successfully than liquid tumours. The majority of clinical trials used to treat infectious diseases use a vaccination method. Monogenic disease trials address a wide range of indications, including cardiovascular, musculoskeletal, haematological, metabolic, and neurological illnesses. . Developments in gene therapy techniques, particularly in countries that are at the forefront of this research, may indicate where future clinical products will go.

Clinical trials for gene therapy are becoming more prevalent. The sector is poised to grow significantly due to new cell and gene therapies, improved technological exploitation across platforms, and quick regulatory processes. Allogeneic stem cell therapies are less expensive and time-consuming for patients than the existing autologous therapies since barriers to therapy, such as graft versus host disease are solved. For instance, the Japanese health system is prepared for the logistical problem of cell and gene therapy (CGTs) by building extensive medical facilities and engaging in significant public-private collaboration to guarantee efficient manufacturing and supply chains.
The Cell and Gene Therapy Catapult, a private organisation founded in 2012 to bridge the gap between clinical trials and full-scale commercialization of CGTs, is growing because of the UK government's expansion efforts. Similarly to this, innovation is already being used to lessen the amount of money and space required for complex, expensive operations.
2022 saw more gene therapies in the late phase and gear up for approval. These therapies include Donaperminogene seltoplasmid, Fordadistrogene movaparvovec, LX101, and TG-C LD which vary across both rare/monogenetic disorders and common disorders. Many gene therapy studies were started in the past year, and few are already scheduled to begin this year. Although the rate of gene therapy trial launches is slowing down compared to launches between 2016 and 2018, this growth implies a sustained increase.
BioIntel360 suggests that funding for adeno-associated viral vectors (AAVs), the common method for delivering gene treatments, keeps growing. H1 2023 may be a breakthrough year for gene therapy as science strives to get past its troubled past of efficacy and safety issues.
In a clinical trial for its recombinant adeno-associated virus gene therapy medication, FT-002, to treat X-linked retinitis pigmentosa, Frontera Therapeutics has reported the dosing of the first participant.
Recombinant adeno-associated virus (AAV) expressing the gene that aids in repairing damaged retinal cell structures and functions and expresses active functioning proteins is administered intravenously as part of the FT-002 therapy. One injection of FT-002 is supposed to stop the disease's progression or improve a patient's vision.

However, the barriers to commercialization are formidable. Commercialization of gene therapies needs to start significantly sooner even several years ahead of expected approval since the go-to-market framework differs from the usual pharma launch strategy. To guarantee that patients have access to these specialist therapies, the market must be prepared by developing new strategies for increasing awareness and training cancer centres, hospitals, and community healthcare providers. Most of the time, development and commercialization by design strategy are required since authorised treatment centres must set up "new to the world" workflows. By gathering user feedback, the "commercialization by design" approach creates procedures that take gene therapy products from clinical manufacturing to commercialization. BioIntel360 points out the need for early attention to the downstream concerns for launch and commercialization even though much of the focus in the field of cell and gene therapy has been on clinical production and logistics.